-
Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-ReducedF Zannad, JP Ferreira, SJ Pocock et al. -
2021 ACC/AHA Key Data Elements and Definitions for Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Heart Failure)B Bozkurt, RE Hershberger, J Butler et al.
-
INTERMACS Profiles and Outcomes Among Non–Inotrope-Dependent Outpatients With Heart Failure and Reduced Ejection FractionA Samman-Tahhan, JS Hedley, AA. McCue et al.
-
Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 StudyKosiborod M, Lam CSP, CVD-REAL Investigators and Study Group.
-
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice GuidelinesWriting Committee Members, PA Heidenreich, B Bozkurt et al.
-
Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failureNR Pugliese, F Paneni, M Mazzola et al.
-
Randomized Evaluation of Heart Failure With Preserved Ejection Fraction Patients With Acute Heart Failure and Dopamine - The ROPA-DOP TrialK Sharma, Stuart D. Russell and on behalf of the Osler Medical Housestaff.
-
Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection FractionShen L, Jhund PS, McMurray JJV et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
